Polar Asset Management Partners Inc. Buys New Position in LivaNova PLC (NASDAQ:LIVN)

Polar Asset Management Partners Inc. bought a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 37,100 shares of the company's stock, valued at approximately $1,949,000. Polar Asset Management Partners Inc. owned about 0.07% of LivaNova as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LIVN. Price T Rowe Associates Inc. MD raised its position in LivaNova by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company's stock valued at $1,736,000 after purchasing an additional 1,980 shares during the period. Hexagon Capital Partners LLC lifted its position in LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after buying an additional 370 shares during the last quarter. Diversified Trust Co increased its position in LivaNova by 7.9% during the second quarter. Diversified Trust Co now owns 13,902 shares of the company's stock valued at $762,000 after acquiring an additional 1,012 shares during the last quarter. Fifth Third Bancorp raised its stake in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after acquiring an additional 332 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of LivaNova by 4.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company's stock worth $27,745,000 after purchasing an additional 20,275 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LIVN shares. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and set a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Finally, Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and a consensus price target of $69.17.

LivaNova Stock Down 1.6 %

Shares of NASDAQ LIVN traded down $0.79 during midday trading on Friday, reaching $49.71. 504,805 shares of the company's stock traded hands, compared to its average volume of 607,831. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 118.36 and a beta of 0.98. The stock's 50 day simple moving average is $52.19 and its 200-day simple moving average is $51.86. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a one year low of $43.15 and a one year high of $64.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.